脉金生物医药科技（上海）有限公司 Wangjin Biomedical Technology (Shanghai) Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED 2024-02-02 22:00
Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata 2023-10-13 20:00
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function 2023-09-21 21:00
David Topper Joined Inmagene as CFO 2023-09-05 20:00
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study 2023-08-18 19:00
Inmagene's OX40 mAb, with an extended half-life and silenced ADCC, enters POC study in Atopic Dermatitis 2023-08-15 22:50
Inmagene to Participate in the Jefferies Healthcare Conference on June 8 2023-05-30 20:00
IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study 2023-04-28 17:00
Izokibep Phase 2b/3 Hidradenitis Suppurative Data Presented at the 2023 American Academy of Dermatology Annual Meeting 2023-03-20 08:41
Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb 2023-02-06 18:00
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004 2022-08-09 12:00
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007 2022-07-06 12:00
Inmagene Receives FDA's IND Clearance for OX40 Antagonist 2022-05-01 06:00
Inmagene files two international patent applications 2021-11-17 18:30
Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China 2021-08-05 14:00
Inmagene R&D Team expands with two new senior members joining the Company 2021-04-07 09:00
Inmagene launched U.S. subsidiary; Dr. Jean-Louis Saillot joined the company. 2021-02-02 14:48
Inmagene Biopharmaceuticals closed $21 million Series B financing, making the total raised to date over $40 million 2020-11-09 08:00
1